EA031652B1 - Способ и система для обработки клеточной культуры - Google Patents
Способ и система для обработки клеточной культуры Download PDFInfo
- Publication number
- EA031652B1 EA031652B1 EA201690602A EA201690602A EA031652B1 EA 031652 B1 EA031652 B1 EA 031652B1 EA 201690602 A EA201690602 A EA 201690602A EA 201690602 A EA201690602 A EA 201690602A EA 031652 B1 EA031652 B1 EA 031652B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- approximately
- cells
- tpf
- cell culture
- pump
- Prior art date
Links
- 238000004113 cell culture Methods 0.000 title claims abstract description 183
- 238000000034 method Methods 0.000 title claims abstract description 136
- 238000012545 processing Methods 0.000 title claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 122
- 239000012530 fluid Substances 0.000 claims abstract description 106
- 238000009295 crossflow filtration Methods 0.000 claims abstract description 12
- 230000002441 reversible effect Effects 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims description 120
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 55
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 55
- 238000005086 pumping Methods 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 230000002572 peristaltic effect Effects 0.000 claims description 31
- 239000011148 porous material Substances 0.000 claims description 24
- 238000004891 communication Methods 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 7
- 238000010924 continuous production Methods 0.000 claims description 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 229940126585 therapeutic drug Drugs 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 381
- 239000001963 growth medium Substances 0.000 description 61
- 239000000835 fiber Substances 0.000 description 57
- 238000009630 liquid culture Methods 0.000 description 52
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 48
- 210000004962 mammalian cell Anatomy 0.000 description 40
- 238000003860 storage Methods 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 27
- 238000005516 engineering process Methods 0.000 description 27
- 230000010412 perfusion Effects 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 21
- 230000007246 mechanism Effects 0.000 description 19
- 239000012528 membrane Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 229920001296 polysiloxane Polymers 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 230000009471 action Effects 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 229910002091 carbon monoxide Inorganic materials 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000003996 Interferon-beta Human genes 0.000 description 10
- 108090000467 Interferon-beta Proteins 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- -1 for example Polymers 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 238000007664 blowing Methods 0.000 description 7
- 229960001388 interferon-beta Drugs 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 241000208202 Linaceae Species 0.000 description 5
- 235000004431 Linum usitatissimum Nutrition 0.000 description 5
- 239000008366 buffered solution Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000002808 molecular sieve Substances 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000002457 bidirectional effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000005571 anion exchange chromatography Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 101100421296 Caenorhabditis elegans set-6 gene Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 102000025171 antigen binding proteins Human genes 0.000 description 2
- 108091000831 antigen binding proteins Proteins 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- 229950002209 efungumab Drugs 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960001743 golimumab Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 108010039650 imiglucerase Proteins 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000000622 polydioxanone Substances 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229950001303 biciromab Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940049197 cerezyme Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 108010089296 galsulfase Proteins 0.000 description 1
- 229960005390 galsulfase Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 102000045921 human GAA Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229960002127 imiglucerase Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940103023 myozyme Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/18—External loop; Means for reintroduction of fermented biomass or liquid percolate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M33/00—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
- C12M33/14—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus with filters, sieves or membranes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/10—Separation or concentration of fermentation products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Water Supply & Treatment (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361878502P | 2013-09-16 | 2013-09-16 | |
| PCT/US2014/055897 WO2015039115A1 (en) | 2013-09-16 | 2014-09-16 | Methods and systems for processing a cell culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201690602A1 EA201690602A1 (ru) | 2016-07-29 |
| EA031652B1 true EA031652B1 (ru) | 2019-02-28 |
Family
ID=51660627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201690602A EA031652B1 (ru) | 2013-09-16 | 2014-09-16 | Способ и система для обработки клеточной культуры |
| EA201892084A EA035665B1 (ru) | 2013-09-16 | 2014-09-16 | Способ и система для обработки клеточной культуры |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892084A EA035665B1 (ru) | 2013-09-16 | 2014-09-16 | Способ и система для обработки клеточной культуры |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20150158907A1 (enExample) |
| EP (1) | EP3047013B1 (enExample) |
| JP (4) | JP6925127B2 (enExample) |
| KR (3) | KR20230142653A (enExample) |
| CN (2) | CN105722967B (enExample) |
| AU (4) | AU2014318420B2 (enExample) |
| BR (2) | BR122021001466B1 (enExample) |
| CA (1) | CA2924332C (enExample) |
| CY (1) | CY1124684T1 (enExample) |
| DK (1) | DK3047013T3 (enExample) |
| EA (2) | EA031652B1 (enExample) |
| ES (1) | ES2891728T3 (enExample) |
| HU (1) | HUE055888T2 (enExample) |
| IL (1) | IL244552B (enExample) |
| MX (2) | MX384020B (enExample) |
| SG (2) | SG11201601899TA (enExample) |
| WO (1) | WO2015039115A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201806083RA (en) | 2013-02-22 | 2018-08-30 | Genzyme Corp | Microcarrier perfusion culturing methods and uses thereof |
| CA2901940A1 (en) | 2013-02-22 | 2014-08-28 | Genzyme Corporation | Microcarrier perfusion culturing methods and uses thereof |
| WO2015175679A2 (en) | 2014-05-13 | 2015-11-19 | Amgen Inc. | Process control systems and methods for use with filters and filtration processes |
| TW202204596A (zh) | 2014-06-06 | 2022-02-01 | 美商健臻公司 | 灌注培養方法及其用途 |
| TW202246486A (zh) | 2014-06-09 | 2022-12-01 | 美商健臻公司 | 種子罐培養法(seed train processes)及其用途 |
| SG11201703265XA (en) | 2014-10-24 | 2017-05-30 | Genzyme Corp | Integrated continuous isolation of fluid streams from sterile process vessels |
| BR112017013423B1 (pt) | 2014-12-22 | 2023-04-11 | Genzyme Corporation | Métodos para cultivo de célula de mamífero |
| JP6457338B2 (ja) * | 2015-05-28 | 2019-01-23 | 株式会社日立製作所 | 液体還流容器、細胞濃縮装置及び細胞濃縮システム |
| EP3397282A4 (en) | 2015-12-30 | 2019-08-07 | Momenta Pharmaceuticals, Inc. | METHODS RELATING TO BIOLOGICA |
| ITUB20160272A1 (it) * | 2016-01-22 | 2017-07-22 | Univ Degli Studi Di Palermo | Bioreattore a perfusione autosufficiente monouso per crescite cellulari 3D |
| US20200289987A1 (en) * | 2016-03-14 | 2020-09-17 | Pendotech | Processing System for Multiple Tangential Flow Filtration Stations in Bioprocessing Applications |
| KR102414290B1 (ko) * | 2016-04-15 | 2022-06-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 세포 보유 장치 및 방법 |
| EP3487977B1 (en) | 2016-07-19 | 2022-09-14 | The Automation Partnership (Cambridge) Limited | Reversible liquid filtration system |
| CN109415673B (zh) * | 2016-07-19 | 2022-09-06 | 自动化合作关系（剑桥）有限公司 | 液体过滤和泵系统 |
| CN106047707B (zh) * | 2016-08-03 | 2018-11-13 | 广州赛泊泰生物技术有限公司 | 贴壁/悬浮型细胞培养单元、装置、系统及方法 |
| TWI675696B (zh) * | 2017-06-01 | 2019-11-01 | 美商Ｅｍｄ密理博公司 | 用於灌注應用之切向流過濾裝置 |
| EA202090740A1 (ru) * | 2017-10-16 | 2020-07-07 | Ридженерон Фармасьютикалз, Инк. | Перфузионный биореактор и связанные с ним способы применения |
| WO2019104071A1 (en) * | 2017-11-22 | 2019-05-31 | Corning Incorporated | Perfusion bioreactor system and perfusion cell culture method |
| US11932842B2 (en) | 2018-02-09 | 2024-03-19 | Global Life Sciences Solutions Usa Llc | Bioprocessing apparatus |
| WO2019155027A1 (en) * | 2018-02-09 | 2019-08-15 | General Electric Company | Apparatus for fluid line management in a bioprocessing system |
| US12077743B2 (en) | 2018-02-09 | 2024-09-03 | Global Life Sciences Solutions Usa Llc | Apparatus for fluid line management in a bioprocessing system |
| US12252682B2 (en) | 2018-02-09 | 2025-03-18 | Global Life Sciences Solutions Usa Llc | System and method for fluid flow management in a bioprocessing system |
| US11920119B2 (en) | 2018-02-09 | 2024-03-05 | Global Life Sciences Solutions Usa Llc | Systems and methods for bioprocessing |
| US11371007B2 (en) * | 2018-02-09 | 2022-06-28 | Global Life Sciences Solutions Usa Llc | System and method for fluid flow management in a bioprocessing system |
| US11414639B2 (en) | 2018-02-09 | 2022-08-16 | Global Life Sciences Solutions Usa Llc | Bioprocessing vessel |
| CN110241012B (zh) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用 |
| TWI898645B (zh) | 2018-05-04 | 2025-09-21 | 美商健臻公司 | 灌注式細胞培養裝置 |
| EP3802780A4 (en) * | 2018-06-01 | 2022-03-23 | Gennova Biopharmaceuticals Limited | PROCEDURE FOR THE PRODUCTION OF RECOMBINANT TNK-TPA BY A PACKED BED PERFUSION SYSTEM |
| CN112584916A (zh) * | 2018-08-29 | 2021-03-30 | 思拓凡瑞典有限公司 | 用于过滤的系统和其相关联的方法 |
| AU2019336148B2 (en) * | 2018-09-06 | 2025-08-14 | Momenta Pharmaceuticals, Inc. | Methods of continuous cell culture |
| CN112703047A (zh) * | 2018-09-21 | 2021-04-23 | 思拓凡瑞典有限公司 | 灌注生物处理系统和其操作方法 |
| MA54093A (fr) * | 2018-11-02 | 2021-09-08 | Wuxi Biologics Ireland Ltd | Procédé de culture cellulaire par perfusion intensifiée avec récolte continue et sans purge cellulaire |
| US10647954B1 (en) | 2018-11-15 | 2020-05-12 | Flaskworks, Llc | Dendritic cell generating apparatus and method |
| CN113474366B (zh) | 2018-12-31 | 2025-01-17 | 动量制药公司 | 产生优特克单抗的方法 |
| CA3126717A1 (en) * | 2019-01-25 | 2020-07-30 | Becton, Dickinson And Company | Methods and apparatus to selectively extract constituents from biological samples |
| KR20210148274A (ko) * | 2019-04-01 | 2021-12-07 | 베링거 인겔하임 인터내셔날 게엠베하 | 통합된 연속적인 재조합 단백질의 제조 |
| WO2020258706A1 (zh) * | 2019-06-28 | 2020-12-30 | 信达生物制药(苏州)有限公司 | 组合式层析装置、无缝连接层析方法和生物制剂的纯化方法 |
| US11566217B2 (en) | 2019-08-13 | 2023-01-31 | Flaskworks, Llc | Duty cycle for cell culture systems |
| MX2022004760A (es) | 2019-10-21 | 2022-07-21 | Flaskworks Llc | Sistemas y métodos para el cultivo de células. |
| EP3878542A1 (en) * | 2020-03-11 | 2021-09-15 | Bayer AG | Filter membranes as antifoam level safeguards |
| KR102230957B1 (ko) * | 2020-05-18 | 2021-03-23 | 경북대학교 산학협력단 | Ev 여과장치 |
| AU2021306319B2 (en) * | 2020-07-08 | 2023-12-14 | Vascular Perfusion Solutions, Inc. | Reciprocating pressure perfusion system and methods |
| WO2022013248A1 (en) * | 2020-07-15 | 2022-01-20 | Global Life Sciences Solutions Usa Llc | Bioprocessing perfusion system having a plurality of filters and method of operating the same |
| CN114058505B (zh) * | 2020-07-30 | 2024-10-01 | 环球生命科技咨询美国有限责任公司 | 新型灌流培养用高密度微载体截留装置和使用方法 |
| US20220119759A1 (en) * | 2020-10-19 | 2022-04-21 | Emd Millipore Corporation | Cascade Tangential Flow Filtration Systems for Perfusion of Cell Culture |
| US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12151024B2 (en) | 2021-01-22 | 2024-11-26 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| CN112831416B (zh) * | 2021-01-29 | 2025-01-10 | 上海睿钰生物科技有限公司 | 一种体外生命维持灌流培养系统及其控制方法 |
| JP2024514468A (ja) | 2021-04-16 | 2024-04-02 | レプリゲン・コーポレーション | ろ過システム及び方法 |
| CN217868904U (zh) * | 2021-04-29 | 2022-11-22 | 尤尼沃尔塞尔斯技术股份公司 | 用于生产和纯化目标生物制剂和用于生产胞外体的系统 |
| EP4370647A1 (en) | 2021-07-15 | 2024-05-22 | Just-Evotec Biologics, Inc. | Bidirectional tangential flow filtration (tff) perfusion system |
| WO2023064464A1 (en) | 2021-10-14 | 2023-04-20 | Pacira Pharmaceuticals, Inc. | Bupivacaine multivesicular liposome formulations and uses thereof |
| EP4174164A1 (en) * | 2021-10-21 | 2023-05-03 | Alit Biotech (Shanghai) Co., Ltd. | Biological filtration systems and controlling methods thereof |
| EP4268943A1 (en) | 2022-04-27 | 2023-11-01 | Levitronix GmbH | A device for tangential flow filtration of a fluid |
| WO2024092004A1 (en) * | 2022-10-26 | 2024-05-02 | National Resilience, Inc. | Bioreactor systems and methods of operating same |
| WO2025122785A1 (en) * | 2023-12-05 | 2025-06-12 | Massachusetts Institute Of Technology | Magnetic resonance relaxometry bioreactor monitoring |
| WO2025134151A1 (en) * | 2023-12-20 | 2025-06-26 | Omnibrx Biotechnologies Private Limited | An apparatus for cell retention and method thereof |
| WO2025164695A1 (ja) * | 2024-02-01 | 2025-08-07 | 国立大学法人東京科学大学 | 細胞培養装置及びそれを用いた細胞培養方法 |
| US12246092B1 (en) | 2024-05-20 | 2025-03-11 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12251468B1 (en) | 2024-05-20 | 2025-03-18 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US12251472B1 (en) | 2024-05-20 | 2025-03-18 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544424B1 (en) * | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| US20110011486A1 (en) * | 2007-12-28 | 2011-01-20 | Societe De Technologie Michelin | Method and Device for Manufacturing a Cable Comprising Two Layers of the In Situ Compound Type |
| WO2014051503A1 (en) * | 2012-09-27 | 2014-04-03 | Ge Healthcare Bio-Sciences Ab | Tangential flow perfusion system |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60804A (ja) * | 1983-06-20 | 1985-01-05 | Poritetsukusu:Kk | ウルトラフイルタ装置 |
| JPS6188872A (ja) * | 1984-10-09 | 1986-05-07 | Snow Brand Milk Prod Co Ltd | 高濃度連続培養方法及び装置 |
| US4885087A (en) * | 1986-11-26 | 1989-12-05 | Kopf Henry B | Apparatus for mass transfer involving biological/pharmaceutical media |
| US6022742A (en) * | 1986-11-26 | 2000-02-08 | Kopf; Henry B. | Culture device and method |
| US5030346A (en) * | 1988-01-15 | 1991-07-09 | Henry Filters, Inc. | Pump for filtration system |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| JPH0531335A (ja) * | 1991-07-30 | 1993-02-09 | Toto Ltd | 分離膜洗浄方法 |
| JP3547715B2 (ja) * | 2001-03-06 | 2004-07-28 | 榮 新垣 | ベクター精製用装置及び方法 |
| AU2003243673B2 (en) * | 2002-06-19 | 2010-01-21 | Northwest Biotherapeutics, Inc. | Tangential flow filtration devices and methods for leukocyte enrichment |
| US7875448B2 (en) * | 2004-01-12 | 2011-01-25 | Single Use Brx, Llc | Bioreactor systems and disposable bioreactor |
| EP1720972B1 (en) * | 2004-03-05 | 2014-01-08 | DSM IP Assets B.V. | Process for cell culturing by continuous perfusion and alternating tangential flow |
| US7662930B2 (en) * | 2005-12-06 | 2010-02-16 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
| GB0606144D0 (en) * | 2006-03-28 | 2006-05-10 | Ge Healthcare Bio Sciences Ab | Automated crossflow filtration method and system |
| PL2343362T5 (pl) * | 2006-07-14 | 2024-12-02 | Patheon Holdings I B.V. | Ulepszony proces hodowli komórek |
| JP5003614B2 (ja) * | 2008-07-03 | 2012-08-15 | 株式会社日立プラントテクノロジー | 生体細胞の分離方法及び培養装置 |
| US9446354B2 (en) * | 2010-08-25 | 2016-09-20 | Repligen Corporation | Device, system and process for modification or concentration of cell-depleted fluid |
| CN103415610B (zh) * | 2011-03-18 | 2016-10-19 | 通用电气健康护理生物科学股份公司 | 用于培养细胞的弹性袋 |
| CN104160013B (zh) * | 2012-01-18 | 2017-07-28 | 拜尔健康护理有限责任公司 | 灌流式生物反应器系统及操作其的方法 |
| KR102059895B1 (ko) * | 2012-02-20 | 2019-12-27 | 바이엘 악티엔게젤샤프트 | 세포를 유지하고 재순환시키기 위한 단방향 분리기 |
-
2014
- 2014-09-16 CN CN201480062402.2A patent/CN105722967B/zh active Active
- 2014-09-16 KR KR1020237033339A patent/KR20230142653A/ko not_active Ceased
- 2014-09-16 ES ES14780959T patent/ES2891728T3/es active Active
- 2014-09-16 EP EP14780959.4A patent/EP3047013B1/en active Active
- 2014-09-16 CN CN202110234907.4A patent/CN113444620B/zh active Active
- 2014-09-16 BR BR122021001466-3A patent/BR122021001466B1/pt active IP Right Grant
- 2014-09-16 CA CA2924332A patent/CA2924332C/en active Active
- 2014-09-16 MX MX2016003440A patent/MX384020B/es unknown
- 2014-09-16 HU HUE14780959A patent/HUE055888T2/hu unknown
- 2014-09-16 SG SG11201601899TA patent/SG11201601899TA/en unknown
- 2014-09-16 KR KR1020227006373A patent/KR102749545B1/ko active Active
- 2014-09-16 JP JP2016542875A patent/JP6925127B2/ja active Active
- 2014-09-16 EA EA201690602A patent/EA031652B1/ru not_active IP Right Cessation
- 2014-09-16 KR KR1020167009570A patent/KR102369211B1/ko active Active
- 2014-09-16 BR BR112016005545-4A patent/BR112016005545B1/pt active IP Right Grant
- 2014-09-16 WO PCT/US2014/055897 patent/WO2015039115A1/en not_active Ceased
- 2014-09-16 AU AU2014318420A patent/AU2014318420B2/en active Active
- 2014-09-16 SG SG10201803601SA patent/SG10201803601SA/en unknown
- 2014-09-16 DK DK14780959.4T patent/DK3047013T3/da active
- 2014-09-16 EA EA201892084A patent/EA035665B1/ru not_active IP Right Cessation
-
2015
- 2015-02-20 US US14/627,674 patent/US20150158907A1/en not_active Abandoned
-
2016
- 2016-03-13 IL IL244552A patent/IL244552B/en active IP Right Grant
- 2016-03-16 MX MX2021007792A patent/MX2021007792A/es unknown
-
2020
- 2020-04-16 AU AU2020202568A patent/AU2020202568B2/en active Active
- 2020-04-17 JP JP2020073759A patent/JP7008746B2/ja active Active
-
2021
- 2021-05-14 US US17/321,128 patent/US20210269477A1/en not_active Abandoned
- 2021-10-13 CY CY20211100884T patent/CY1124684T1/el unknown
-
2022
- 2022-01-07 JP JP2022001359A patent/JP7227406B2/ja active Active
- 2022-08-25 AU AU2022221495A patent/AU2022221495A1/en not_active Abandoned
-
2023
- 2023-02-08 JP JP2023017253A patent/JP7685543B2/ja active Active
-
2024
- 2024-09-03 AU AU2024219335A patent/AU2024219335A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544424B1 (en) * | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| US20110011486A1 (en) * | 2007-12-28 | 2011-01-20 | Societe De Technologie Michelin | Method and Device for Manufacturing a Cable Comprising Two Layers of the In Situ Compound Type |
| WO2014051503A1 (en) * | 2012-09-27 | 2014-04-03 | Ge Healthcare Bio-Sciences Ab | Tangential flow perfusion system |
Non-Patent Citations (1)
| Title |
|---|
| "Conversion of Bioreactors to Continuous Perfusion Using Hollow Fiber Cell Separators", 1 January 1989 (1989-01-01), XP055155533, Retrieved from the Internet:URL:http://www.spectrumlabs.com/lit/CPAG.pdf [retrieved on 2014-11-27], page 22-23 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA031652B1 (ru) | Способ и система для обработки клеточной культуры | |
| RU2694327C2 (ru) | Способ культивирования в системе посевных ферментеров (варианты) | |
| RU2713126C2 (ru) | Способ предотвращения контаминации системы | |
| HK40057516A (en) | Methods and systems for processing a cell culture | |
| HK40057516B (zh) | 用於处理细胞培养物的方法和系统 | |
| RU2786997C2 (ru) | Процессы культивирования в системе посевных ферментеров и способы их применения | |
| RU2811104C2 (ru) | Способы культивирования клетки млекопитающего | |
| HK1222672B (en) | Methods and systems for processing a cell culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |